The progress of interleukin-33 on liver diseases / 中华肝胆外科杂志

ABSTRACT

Interleukin-33 (IL-33) is a multifunctional gene in the interleukin-1 family and is widely expressed in human tissues. Its receptor is ST2, is associated with asthma, diabetes, Alzheimer's disease, cardiovascular disease, inflammatory bowel disease, and cancer. IL-33, enhancing lipid metabolism and down-regulating adipogenic gene expression by inducing Th2 cytokine production, plays a protective role in fatty liver. In hepatitis, the IL-33/NKT/IFN-γ pathway exacerbates mouse hepatitis. While, the IL-33/ILC2/IL-13/STAT6 pathway reduces liver damage. The IL-33/ILC2/IL-13/IL-4Rα/STAT6 axis plays a facilitating role in cirrhosis. In liver cancer, IL-33/ILC2/IL-13 signaling pathway is found to promote cholangiocarcinoma in a favorable pathological environment, and hepatocellular carcinoma occurs by IL-33/IL-6/JAK/STAT/Mcl-1 signaling pathway.